CD8A and breast cancer: Beyond their effects on ER signaling, HDACi have been suggested in preclinical studies to decrease Tregs, induce PD-L1 expression on tumor cells, and alter the composition of TILs, specifically inducing CD8+ T-cells in vitro and in vivo in BC models42.